Skip to main content

Remote Job Finders (RJF)

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% for the period.
Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock
Scroll to top